5-LIPOXYGENASE PRODUCTS IN ASTHMATIC IMMUNE RESPONSE

5-脂氧合酶产品在哮喘免疫反应中的作用

基本信息

  • 批准号:
    6373825
  • 负责人:
  • 金额:
    $ 25.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-04-01 至 2003-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: The 5-lipoxygenase (5-LO) products, the leukotriene (LT)s, are clearly important participants in the pulmonary inflammatory process in patients with asthma. We have developed a protocol for administration of ovalbumin (OVA_ as allergen to induce late-phase allergen-specific pulmonary disease in normal BAL:B/c and C57BL/6 mice. OVA-treated mice display a disease strikingly similar to allergen-induced human asthma. In our mouse model of asthma, we have found that leukotrienes are key mediators of the mucus release and eosinophil infiltration of the airways. With the availability of mutant mice deficient in 5-LO and both isoforms of cyclooxygenase (COX) (together wit specific inhibitors/antagonists of the lipid mediators), we will determine the contribution of the 5-LO pathway to the induction and resolution of allergic airway inflammation and AHR. These studies will be performed in both our standard protocol and a long-term model of allergen-induced lung fibrosis in mice. Our goal will be to define immune mechanisms by which leukotrienes influences the activation and effector functions of T cells and dendritic cells, key cells in the mediation of allergic airway inflammation. Our specifi aims are as follows: Specific Aim 1. To characterize further the role of the 5-LO pathway in allergic pulmonary inflammation and AHR. We will examine these questions: a) Will intrapulmonary 5-LO pathway blockade prevent AHR? b) Will 5-LO pathway blockade resolve ongoing allergic airway inflammation? and c) Wil 5-LO pathway blockade prevent allergen-induced lung fibrosis? Specific Aim 2. To determine the interrelationship of the 5-LO pathway with COX-2 pathway and platelet activating factor (PAF) in the mediation of allergic airway inflammation and AHR. The following questions will be studied: a) Is COX-2 pathway activation important in development of allergic inflammation and AHR? and b) Will blockade of secretory phospholipase A2 (sPLA2) and PAF inhibit allergic lung inflammation and AHR? and Specific Aim 3. To determine the mechanisms by which leukotriene inhibition blocks allergic pulmonary inflammation and AHR in the murine model of asthma. We will study these questions: a) Will 5-LO pathway blockade prevent allergen-induced T cell proliferation and/or cytokine generation necessary for airway inflammation and AHR? and b) Is 5-LO pathway activation required for adoptive transfer of AHR b T cells? The more specific our knowledge of the biochemical and immunological changes becomes, the more likely it is that specific interventions producing more benefit than harm in reducing leukotriene-reduced inflammation, will be found.
描述:5-脂氧合酶(5-LO)产物白三烯(LT)s是

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM REED HENDERSON其他文献

WILLIAM REED HENDERSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM REED HENDERSON', 18)}}的其他基金

Chemogenomics to Identify New Molecular Targets in PF
化学基因组学识别 PF 的新分子靶点
  • 批准号:
    6802325
  • 财政年份:
    2003
  • 资助金额:
    $ 25.64万
  • 项目类别:
Chemogenomics to Identify New Molecular Targets in PF
化学基因组学识别 PF 的新分子靶点
  • 批准号:
    7116884
  • 财政年份:
    2003
  • 资助金额:
    $ 25.64万
  • 项目类别:
Chemogenomics to Identify New Molecular Targets in PF
化学基因组学识别 PF 的新分子靶点
  • 批准号:
    6664141
  • 财政年份:
    2003
  • 资助金额:
    $ 25.64万
  • 项目类别:
Chemogenomics to Identify New Molecular Targets in PF
化学基因组学识别 PF 的新分子靶点
  • 批准号:
    6942714
  • 财政年份:
    2003
  • 资助金额:
    $ 25.64万
  • 项目类别:
5-LIPOXYGENASE PRODUCTS IN ASTHMATIC IMMUNE RESPONSE
5-脂氧合酶产品在哮喘免疫反应中的作用
  • 批准号:
    6510827
  • 财政年份:
    1998
  • 资助金额:
    $ 25.64万
  • 项目类别:
PHASE 2A STUDY OF RPAF AH IN ALLERGEN CHALLENGE IN MILD ASTHMATICS
RPAF AH 在轻度哮喘患者过敏原挑战中的 2A 期研究
  • 批准号:
    6113126
  • 财政年份:
    1998
  • 资助金额:
    $ 25.64万
  • 项目类别:
5-Lipoxygenase Products in Asthmatic Immune Response
5-脂氧合酶产品在哮喘免疫反应中的作用
  • 批准号:
    7018494
  • 财政年份:
    1998
  • 资助金额:
    $ 25.64万
  • 项目类别:
5-Lipoxygenase Products in Asthmatic Immune Response
5-脂氧合酶产品在哮喘免疫反应中的作用
  • 批准号:
    7217301
  • 财政年份:
    1998
  • 资助金额:
    $ 25.64万
  • 项目类别:
5-Lipoxygenase Products in Asthmatic Immune Response
5-脂氧合酶产品在哮喘免疫反应中的作用
  • 批准号:
    6780018
  • 财政年份:
    1998
  • 资助金额:
    $ 25.64万
  • 项目类别:
5-LIPOXYGENASE PRODUCTS IN ASTHMATIC IMMUNE RESPONSE
5-脂氧合酶产品在哮喘免疫反应中的作用
  • 批准号:
    2887722
  • 财政年份:
    1998
  • 资助金额:
    $ 25.64万
  • 项目类别:

相似海外基金

Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
  • 批准号:
    2901112
  • 财政年份:
    2024
  • 资助金额:
    $ 25.64万
  • 项目类别:
    Studentship
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
  • 批准号:
    485322
  • 财政年份:
    2023
  • 资助金额:
    $ 25.64万
  • 项目类别:
    Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
  • 批准号:
    493135
  • 财政年份:
    2023
  • 资助金额:
    $ 25.64万
  • 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
  • 批准号:
    493526
  • 财政年份:
    2023
  • 资助金额:
    $ 25.64万
  • 项目类别:
    Operating Grants
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
  • 批准号:
    495593
  • 财政年份:
    2023
  • 资助金额:
    $ 25.64万
  • 项目类别:
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
  • 批准号:
    485504
  • 财政年份:
    2023
  • 资助金额:
    $ 25.64万
  • 项目类别:
    Salary Programs
Mechanistic Study of Inspiratory Training in Childhood Asthma
儿童哮喘吸气训练机制研究
  • 批准号:
    10637048
  • 财政年份:
    2023
  • 资助金额:
    $ 25.64万
  • 项目类别:
Early life exposure to metal mixtures: impacts on asthma and lungdevelopment
生命早期接触金属混合物:对哮喘和肺部发育的影响
  • 批准号:
    10678307
  • 财政年份:
    2023
  • 资助金额:
    $ 25.64万
  • 项目类别:
Lung resident Treg suppression of Th2 resident memory T cells in allergic asthma
过敏性哮喘中肺常驻 Treg 对 Th2 常驻记忆 T 细胞的抑制
  • 批准号:
    10664599
  • 财政年份:
    2023
  • 资助金额:
    $ 25.64万
  • 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
  • 批准号:
    10813753
  • 财政年份:
    2023
  • 资助金额:
    $ 25.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了